Skip to main content
    E

    Exelixis Inc (EXEL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $67.10
    -1.90 (-2.75%)

    Market Cap: $16.84B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Exelixis Inc (EXEL) Financials: Revenue, Profit and Cash Flow

    Updated Aug 5, 2026. Financial statements from company filings, amounts in US dollars.

    Exelixis reported revenue of $2.32B for the fiscal year ended Dec 31, 2025, up 7.0% from the year before. That year, net income was $782.57M with a net margin of 33.7%, operating cash flow was $884.27M and free cash flow was $875.84M. The quarter ended Jun 30, 2026 had revenue of $628.69M and net income of $212.05M.

    Revenue and Margins

    The operating margin was 37.6% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $191.45M, a compound annual rate of 31.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$2.32B+7.0%96.4%37.6%33.7%
    Dec 2024$2.17B+18.5%96.5%27.9%24.0%
    Dec 2023$1.83B+13.6%96.0%9.3%11.4%
    Dec 2022$1.61B+12.3%96.4%12.5%11.3%
    Dec 2021$1.43B+45.3%96.3%20.0%16.1%
    Dec 2020$987.54M+2.0%96.3%11.1%11.3%
    Dec 2019$967.77M+13.3%96.6%38.2%33.2%
    Dec 2018$853.83M+88.7%96.9%51.4%80.8%
    Dec 2017$452.48M+136.3%96.7%36.7%34.1%
    Dec 2016$191.45MN/A96.6%-14.7%-36.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 50.1% from the year before. In the quarter ended Jun 2026, net income rose 14.7% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$2.32B$2.17B$1.83B$1.61B$1.43B$987.54M$967.77M$853.83M$452.48M$191.45M
    Cost of revenue$83.70M$76.22M$72.55M$57.91M$52.87M$36.27M$33.10M$26.35M$15.07M$6.55M
    Gross profit$2.24B$2.09B$1.76B$1.55B$1.38B$951.27M$934.68M$827.48M$437.41M$184.90M
    Research and development$825.00M$910.41M$1.04B$891.81M$693.72M$547.85M$336.96M$182.26M$112.17M$95.97M
    Operating income$872.19M$604.62M$170.88M$201.48M$286.67M$110.06M$369.47M$438.86M$165.91M-$28.12M
    Net income$782.57M$521.27M$207.76M$182.28M$231.06M$111.78M$321.01M$690.07M$154.23M-$70.22M
    EBITDA$901.05M$633.29M$196.69M$222.16M$300.11M$120.11M$378.50M$444.17MN/AN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$628.69M$610.81M$598.66M$597.75M$568.26M$555.45M$566.75M$539.54M$637.18M$425.23M$479.65M$471.92M
    Gross profit$608.03M$590.86M$572.18M$579.18M$548.79M$536.27M$546.79M$522.21M$619.51M$403.97M$457.90M$453.15M
    Operating income$248.41M$251.34M$235.22M$236.54M$213.58M$186.86M$163.21M$136.07M$275.87M$29.46M$81.79M-$17.58M
    Net income$212.05M$210.47M$244.53M$193.58M$184.85M$159.62M$139.86M$117.97M$226.12M$37.32M$85.52M$1.04M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $482.49M were 17.0% of total assets of $2.84B, against total liabilities of $683.10M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$2.84B$2.95B$2.94B$3.07B$2.62B$2.14B$1.89B$1.42B$655.29M$595.74M
    Current assets$1.44B$1.47B$1.32B$1.62B$1.83B$1.45B$1.01B$897.02M$484.87M$469.00M
    Cash and equivalents$482.49M$217.37M$262.99M$501.19M$647.17M$319.22M$266.50M$314.77M$183.16M$151.69M
    Total liabilities$683.10M$703.49M$678.45M$583.06M$405.62M$258.22M$199.70M$134.83M$370.33M$506.42M
    Short-term debtN/A$25.01M$25.71M$17.66M$8.74M$3.02M$2.73M$56.85M$57.46M$189.12M
    Long-term debtN/AN/AN/AN/AN/AN/AN/A$12.10M$408.00K$0
    Shareholder equity$2.16B$2.24B$2.26B$2.49B$2.21B$1.88B$1.69B$1.29B$284.96M$89.32M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$2.49B$2.59B$2.84B$2.82B$2.68B$2.84B$2.95B$2.96B$2.77B$2.80B$2.94B$2.98B
    Total liabilities$650.47M$657.85M$683.10M$662.85M$644.54M$706.22M$703.49M$684.86M$653.39M$675.74M$678.45M$629.29M
    Cash and equivalents$281.45M$226.15M$482.49M$376.30M$164.43M$183.75M$217.37M$258.35M$198.46M$259.56M$262.99M$396.86M
    Shareholder equity$1.84B$1.94B$2.16B$2.16B$2.03B$2.13B$2.24B$2.28B$2.12B$2.13B$2.26B$2.35B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 99.0% of operating cash flow. Share repurchases came to 108.2% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$884.27M$699.97M$333.32M$362.61M$400.80M$208.98M$526.96M$415.72M$165.61M$210.40M
    Capital expenditures$8.43M$28.43M$40.47M$27.71M$54.23M$30.34M$12.83M$33.30M$21.14M$1.70M
    Free cash flow$875.84M$671.54M$292.86M$334.91M$346.58M$178.64M$514.12M$382.42M$144.47M$208.70M
    Share repurchases$947.51M$652.03M$550.38M$0$0N/AN/AN/AN/AN/A
    Investing cash flow$350.44M-$116.78M-$26.95M-$524.41M-$42.88M-$131.22M-$587.25M-$297.85M$36.80M-$214.55M
    Financing cash flow-$969.59M-$628.81M-$546.05M$586.00K-$14.80M-$25.13M$12.55M$9.69M-$169.93M$15.70M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow$307.74M$251.84M$333.51M$290.32M$48.99M$211.44M$240.26M$271.34M$119.55M$68.82M$10.57M$117.37M
    Capital expenditures$6.82M$1.51M$1.16M$1.48M$2.84M$2.95M$3.98M$8.20M$6.57M$9.69M$13.13M$9.37M
    Free cash flow$300.93M$250.34M$332.36M$288.84M$46.16M$208.49M$236.29M$263.14M$112.98M$59.13M-$2.56M$107.99M
    Last 12 quarters

    Frequently Asked Questions About EXEL

    What is Exelixis' annual revenue?

    Exelixis reported revenue of $2.32B for the fiscal year ended Dec 31, 2025.

    How fast is Exelixis' revenue growing?

    Revenue was up 7.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 12.9%.

    Is Exelixis profitable?

    Yes. Exelixis reported net income of $782.57M for the fiscal year ended Dec 31, 2025, with a net margin of 33.7%.

    How much free cash flow does EXEL generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $884.27M minus capital expenditures of $8.43M produced free cash flow of $875.84M.

    How much debt does Exelixis have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $482.49M.